Genetic Variants and Therapeutic Response to Anti–TNF-α Agents in Juvenile Idiopathic Arthritis

Pregnolato, Francesca; Chighizola, Cecilia Beatrice; Giani, Teresa; Costi, Stefania; Marino, Achille; Cimaz, Rolando

doi:10.1097/rhu.0000000000001835

Cited by 1 publication

(1 citation statement)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similarly, the notion of a window of opportunity in pJIA is widespread and has contributed to the implementation of treat-to-target strategies in pJIA, yet evidence supporting its existence is rather indirect [ 73 ]. Genetic studies investigating a possible link between specific SNPs and response to bDMARDs have been performed, but each have involved <100 JIA patients [ 76 ].…”

Section: Response To Specific Targeted Therapies In Pjiamentioning

confidence: 99%

Patterns and determinants of response to novel therapies in juvenile and adult-onset polyarthritis

Triaille,

Quartier,

De Somer

et al. 2023

Rheumatology

View full text Add to dashboard Cite

Biological and targeted synthetic disease-modifying anti-rheumatic drugs (b/tsDMARDs) have revolutionized the management of multiple rheumatic inflammatory conditions. Amongst these, polyarticular juvenile idiopathic arthritis (pJIA) and rheumatoid arthritis (RA) display similarities in terms of disease pathophysiology and response pattern to b/tsDMARDs. Indeed, therapeutic efficacy of novel targeted drugs is variable among individual patients, in both RA and pJIA. Mechanisms and determinants of this heterogeneous response are diverse and complex, such that development of true “precision”-medicine strategies has proven highly challenging. In this review, we will discuss pathophysiological, patient-specific, drug-specific and environmental factors contributing to individual therapeutic response in polyarticular JIA in comparison to what is known in RA. Although some biomarkers have been identified that stratify for the likelihood of either therapeutic response or non-response, few have proved useful in clinical practice so far, likely due to the complexity of treatment-response mechanisms. Consequently, we propose a pragmatic, patient-centered and clinically-based approach, i.e. personalized instead of biomarker-based precision medicine in JIA.

show abstract

Section: Response To Specific Targeted Therapies In Pjiamentioning

confidence: 99%